About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Phase II Study of TAS-106 to Treat Head and Neck Cancer

NCT00737360·5 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Taiho Pharmaceutical Co., Ltd.

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Age 18 ≤ years old at study entry
Histologically confirmed head and neck carcinoma
Received prior platinum based regimen and developed disease progression or recurrence
Measurable disease according to RECIST guidelines

You may not be if

Radiological or clinical evidence of brain involvement or leptomeningeal disease
≥ grade 2 peripheral neuropathy
History of another malignancy

The record

StatusTerminated

PhasePhase 2

Taking part27

StartedAug 2008

UpdatedSep 5, 2012

Conditions

Head and Neck Cancer

Where5

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Orleans Street, Baltimore, Maryland, United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
The Chinese University of Hong Kong, Prince of Wales Hospital
Shatin, Hksar, Hong Kong

Clareo Health | Phase II Study of TAS-106 to Treat Head and Neck Cancer